Compare ARK Genomic Revolution ETF (ARKG) vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs State Street SPDR Bloomberg 1-3 Month T-Bill ETF — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.5. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, State Street SPDR Bloomberg 1-3 Month T-Bill ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | BIL | |
|---|---|---|
Sector | Sector/Thematic | Fixed Income |
52-Week High | $43.57 | $91.77 |
52-Week Low | $23.09 | $91.27 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
BIL (SPDR Bloomberg 1-3 Month T-Bill ETF) trades at $91.50 with minimal daily movement, reflecting its stable Treasury bill portfolio. The ETF maintains consistent $0.27 quarterly dividends and shows bearish technical signals despite neutral oscillators. Recent market focus compares short-term Treasury ETFs like BIL against money market alternatives as investors seek yield amid Federal Reserve policy uncertainty.
BIL offers low-risk cash parking with Treasury bill exposure, but faces pressure from potential Fed rate hikes that could impact short-term yields. The ETF's stability appeals to risk-averse investors, though higher-yielding alternatives may emerge if rates rise further. Current technical weakness suggests cautious near-term positioning despite fundamental safety.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →
